BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25

• 

  Manucturing

  Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency

  While Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate believing a competing product can make the supply chain more resilient.

  August 25, 2026

   · 

  4 min read

   · 

  Nick Paul Taylor
• 

  Job Trends

  Massachusetts biopharma jobs, including R&D positions, fell in 2025: Report

  After barely growing in 2024, biopharma employment in Massachusetts dropped 3.1% last year. R&D jobs dipped even more, by 3.9%. Biomanufacturing, however, went up.

  August 25, 2026

   · 

  3 min read

   · 

  Angela Gabriel
• Press Releases

  Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

  August 25, 2026

   · 

  9 min read
• Press Releases

  The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

  August 25, 2026

   · 

  8 min read
• Press Releases

  Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength

  August 25, 2026

   · 

  4 min read
• Press Releases

  FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

  August 25, 2026

   · 

  17 min read
• Press Releases

  Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

  August 25, 2026

   · 

  6 min read
• Press Releases

  Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules

  August 25, 2026

   · 

  4 min read
• Press Releases

  Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases

  August 25, 2026

   · 

  5 min read
• Press Releases

  Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage

  August 25, 2026

   · 

  6 min read